Leading the clinical development of 
fibrinolysis without bleeding 
to change the treatment paradigm for
ischemic stroke and heart attack.

Thrombolytic Science (TSI) is a private, clinical stage, vascular medicine & biotech company.

Our Focus

Current treatment options for patients experiencing a stroke or heart attack are limited and delay the
re-establishment of blood flow.

TSI is dedicated to transforming standards of care, by bringing a simple intravenous biotherapy to the patient, closer to the time of onset.

 

TSI’s bio-inspired solution is 

  • A low dose, efficacious, safer dual thrombolytic Rx

  • Based on a clinically validated mechanism

  • To be given on suspicion of a stroke or heart attack

 

Clinical Trials

TSI recently completed a Phase 1 clinical study confirming the safety and tolerability of its novel tPA / HisproUK dual regimen.  

 

TSI's dual regimen is currently being tested in two Phase 2 clinical trials, one in ischemic stroke patients, and an another in patients with acute myocardial infarction.

 
 

Science

tPA's biological role is limited to degrading the surface of the clot.


With TSI’s regimen, once this occurs, the small amount of tPA used is rapidly cleared from the blood flow. HisproUK, TSI's compound, exclusively targets the now degraded clot and dissolves it.

 

Should there be no degraded clot, as in the case of stroke mimics or a hemorrhagic stroke, HisproUK will remain safely in its inactive pro enzymatic form before being cleared in minutes from the blood flow. 

 

TSI's thrombolytic regimen could therefore be given safely on simple suspicion of an ischemic stroke, as soon as possible after stroke onset.

 

Team

Management & Board of Directors

Alexis Wallace, MScEng, MBA

President and Chief Executive Officer,

Director and Co-founder

Victor Gurewich, MD

Chief Scientific Officer, Director and Co-founder

Michael Woehler.jpeg

Michael Woehler, PhD

Non-Executive Chairman

Advisory Board

Annalisa Jenkins, MBBS, FRCP

Chairman of the Court,

London School of Hygiene &

Tropical Medicine

Non-Executive Chairman,

Cocoon Biotech

api-bioimage-gregory-del-zoppo.jpg

Gregory J. del Zoppo, M.D.

Professor of Medicine, Hematology

Adjunct Professor, Neurology, 

Washington University

James E. Muller, M.D.

Senior Lecturer,

Harvard Medical School, Former Chief Medical Officer, Chairman & Founder, InfraReDx

1985 Nobel Peace Prize

C. Michael Gibson, M.D.

President & CEO,

Baim Institute for Clinical Research

Professor of Medicine,

Harvard Medical School

Chairman & Founder, PERFUSE

 

Publications

 

VIEW>  Gurewich V. Therapeutic Fibrinolysis: How Efficacy and Safety Can Be Improved. JACC 2016.

VIEW>  Bogarty P, Brophy J. STEMI Treatment 2016: Is Outcome Improvement Stalling and If So, Why? DOI 2016.

VIEW>  Pannell R, Li S, Gurewich V. Highly effective fibrinolysis by a sequential synergistic combination of mini-dose tPA                     plus low-dose mutant proUK. PLoS One. 2015; 10(3):e0122018.

VIEW>  Tomasi S, Sarmientos P, Giorda G, Gurewich V, Vercelli A. Mutant prourokinase with adjunctive C1-inhibitor is an                     effective and safer alternative to tPA in rat stroke. PLoS One. 2011; 6(7):e21999

 
 

Contact

Thrombolytic Science, LLC
763D, Concord Avenue
Cambridge, MA 02138

Email: info@tsillc.net

© 2020 TSI Inc. 

  • Twitter
  • LinkedIn